<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="121164">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02070471</url>
  </required_header>
  <id_info>
    <org_study_id>LG-CYCL002</org_study_id>
    <nct_id>NCT02070471</nct_id>
  </id_info>
  <brief_title>Phase 2 Study to Evaluate the Efficacy, Safety and PK of Intravenous Single Injection LC28-0126 Immediately Before PCI in STEMI Patients</brief_title>
  <official_title>A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Intravenous Single Injection LC28-0126 Immediately Before PCI (Percutaneous Coronary Intervention) in Patients With STEMI(ST-segment Elevation Myocardial Infarction)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Life Sciences</source>
  <oversight_info>
    <authority>South Korea: Ministry of Food and Drug Safety</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the efficacy, Safety and Pharmacokinetics of Intravenous single injection LC28-0126
      immediately before PCI (Percutaneous Coronary Intervention) in Patients with STEMI
      (ST-segment Elevation Myocardial Infarction)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>AUC of CK-MB for 72 hours post PCI</measure>
    <time_frame>pre PCI, PCI 0h, 6h, 12h, 18h, 24h, 48h, 72h</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC of Troponin I and CK for 72h post PCI</measure>
    <time_frame>pre PCI, PCI 0h, 6h, 12h, 18h, 24h, 48h, 72h</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infarct size and myocardial function assessed by CMR and Echocardiogram</measure>
    <time_frame>Day 4, 30</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>ST-segment Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>LC28-0126 Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LC28-0126 Dose A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LC28-0126 Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LC28-0126 Dose B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LC28-0126 Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LC28-0126 Dose C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LC28-0126 Dose A</intervention_name>
    <description>LC28-0126 Dose A</description>
    <arm_group_label>LC28-0126 Dose A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LC28-0126 Dose B</intervention_name>
    <description>LC28-0126 Dose B</description>
    <arm_group_label>LC28-0126 Dose B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LC28-0126 Dose C</intervention_name>
    <description>LC28-0126 Dose C</description>
    <arm_group_label>LC28-0126 Dose C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 20 and  75

          -  Within 12 hours after the onset of chest pain

          -  ST-segment elevation of more than 0.1 mV in two contiguous leads or new LBBB(left
             bundle-branch block) patients

          -  Signed for written informed consent

        Exclusion Criteria:

          -  Left Main disease

          -  Multi-vessel disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyo-Soo Kim, M.D., Ph.D.</last_name>
      <phone>82-2-2072-2226</phone>
    </contact>
    <investigator>
      <last_name>Hyo-Soo Kim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 13, 2014</lastchanged_date>
  <firstreceived_date>February 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
